Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited Fundamental Analysis
Sino Biopharmaceutical Limited (SBMFF) shows moderate financial fundamentals with a PE ratio of 26.86, profit margin of 12.67%, and ROE of 11.85%. The company generates $30.3B in annual revenue with strong year-over-year growth of 10.18%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SBMFF's fundamental strength across five key dimensions:
Efficiency Score
WeakSBMFF struggles to generate sufficient returns from assets.
Valuation Score
ModerateSBMFF shows balanced valuation metrics.
Growth Score
ExcellentSBMFF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSBMFF maintains a strong and stable balance sheet.
Profitability Score
WeakSBMFF struggles to sustain strong margins.
Key Financial Metrics
Is SBMFF Expensive or Cheap?
P/E Ratio
SBMFF trades at 26.86 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SBMFF's PEG of 0.10 indicates potential undervaluation.
Price to Book
The market values Sino Biopharmaceutical Limited at 3.12 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 18.17 times EBITDA. This signals the market has high growth expectations.
How Well Does SBMFF Make Money?
Net Profit Margin
For every $100 in sales, Sino Biopharmaceutical Limited keeps $12.67 as profit after all expenses.
Operating Margin
Core operations generate 20.12 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.85 in profit for every $100 of shareholder equity.
ROA
Sino Biopharmaceutical Limited generates $5.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sino Biopharmaceutical Limited produces operating cash flow of $3.14B, showing steady but balanced cash generation.
Free Cash Flow
Sino Biopharmaceutical Limited produces free cash flow of $2.87B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.16 in free cash annually.
FCF Yield
SBMFF converts 2.80% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
26.86
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.12
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.36
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.36
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How SBMFF Stacks Against Its Sector Peers
| Metric | SBMFF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 26.86 | 29.45 | Neutral |
| ROE | 11.85% | 779.00% | Weak |
| Net Margin | 12.67% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.36 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.36 | 4.65 | Neutral |
| ROA | 5.17% | -19344.00% (disorted) | Weak |
SBMFF outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sino Biopharmaceutical Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-32.85%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-57.97%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
Declining